Cassava Sciences, Inc.
SAVA
SAVA: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
moreShow SAVA Financials
Recent trades of SAVA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by SAVA's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Method of inhibiting tau phosphorylation May. 30, 2023
-
Patent Title: Solid polymorphs of a flna-binding compound and its hydrochloride salts Jun. 28, 2022
-
Patent Title: Cocrystals of naloxone and naltrexone Aug. 24, 2021
-
Patent Title: Method of inhibiting tau phosphorylation Sep. 01, 2020
Federal grants, loans, and purchases
Followers on SAVA's company Twitter account
Number of mentions of SAVA in WallStreetBets Daily Discussion
Recent insights relating to SAVA
Recent picks made for SAVA stock on CNBC
ETFs with the largest estimated holdings in SAVA
Flights by private jets registered to SAVA